Yohimbine

Introduction Overview

Generic Name

Yohimbine

Brand Name

Yohimbe

Dosage Form

Oral tablet

Drug Class

Impotence agents (Alpha-2 Adrenergic Blocker)

Pharmacokinetics

Absorption:
Yohimbine is administered orally and exhibits reasonably rapid absorption through the gastrointestinal tract. Studies have indicated that oral bioavailability is subject to first-pass hepatic metabolism, which may result in variable plasma concentrations between individuals. Peak plasma concentrations are generally reached within 30 to 60 minutes post-ingestion. The absorption kinetics can be influenced by factors such as gastric pH and the presence of food, though clinically significant alterations are not well-defined.

Distribution:
Following absorption, yohimbine is moderately distributed into body tissues. It is lipophilic, allowing it to cross biological membranes and distribute into well-perfused organs, including the central nervous system, which corresponds to its pharmacodynamic effects on neuronal alpha-2 adrenergic receptors. Plasma protein binding is moderate to low, enabling a relatively free fraction to exert pharmacological action. The volume of distribution is estimated to be in the range compatible with extensive tissue distribution.

Metabolism:
Yohimbine undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzymatic system, particularly CYP2D6 isoenzyme. The biotransformation results in several metabolites, some of which are considered inactive, while others may have minor pharmacological activity. Genetic polymorphisms in CYP2D6 can significantly affect the metabolism rate, potentially influencing both efficacy and toxicity. Co-administration with CYP2D6 inhibitors or inducers can alter yohimbine plasma levels.

Elimination:
The drug and its metabolites are predominantly eliminated via renal excretion. The elimination half-life ranges approximately from 0.5 to 2 hours, depending on individual metabolic capacity and renal function. Clearance may be prolonged in patients with hepatic or renal impairment, necessitating careful monitoring. The relatively short half-life supports a dosing schedule of multiple times per day to maintain therapeutic plasma levels.

Dosage Forms

Available Dosage Forms:
Yohimbine is primarily available as oral tablets. No standardized dosage form variations such as liquids or extended-release formulations are commonly marketed. Tablets usually contain doses suitable for titration based on clinical response.

Dosages for Adults and Adolescents:
Adult dosing typically starts at 5.4 mg per day divided into two or three doses, with careful titration to response and tolerance. Doses can be adjusted up to 6 mg three times daily depending on effectiveness and side effects. No formal dosage recommendations exist for pediatric or adolescent populations, and use in these age groups is not standard.

Specific Patient Populations:
In elderly patients, yohimbine has not demonstrated altered pharmacodynamics or safety profiles, but caution is advised due to comorbidities. Patients with hepatic or renal impairment may require dose adjustments due to altered metabolism and excretion. Use during pregnancy is not well established, and the drug is generally not recommended. In individuals with cardiovascular disease (e.g., hypertension, angina), dose adjustment or avoidance is warranted due to the risk of exacerbating these conditions.

Mechanism Of Action

Yohimbine is an alkaloid that functions primarily as a selective antagonist of alpha-2 adrenergic receptors located presynaptically on adrenergic nerve terminals. By blocking these inhibitory autoreceptors, it prevents the negative feedback inhibition of norepinephrine release, thereby increasing sympathetic outflow and enhancing norepinephrine availability at postsynaptic receptors. This increased adrenergic stimulation leads to vasodilation in peripheral tissues, especially within the penile vasculature, which underlies its clinical use in erectile dysfunction.

At the cellular level, yohimbine's blockade of alpha-2 receptors causes an increase in intracellular cyclic AMP due to enhanced norepinephrine signaling, promoting smooth muscle relaxation in arterioles and enhancing blood flow. This pharmacologic action contrasts with alpha-1 adrenergic receptor antagonists, which have different mechanisms resulting in vasodilation.

Biochemically, yohimbine may also interact with several other receptors, including some serotonin (5-HT1A) and dopamine receptors, which may contribute to its central nervous system stimulant effects, such as increased alertness and anxiogenic potential. These off-target interactions can influence mood and behavior and are relevant when considering neuropsychiatric side effects.

Clinical studies have demonstrated that yohimbine's efficacy in improving erectile function stems from its ability to increase penile blood flow via sympathetic modulation. Comparative investigations with other impotence agents show differing mechanisms; for example, phosphodiesterase type 5 inhibitors increase nitric oxide-mediated vasodilation, whereas yohimbine acts upstream by modulating adrenergic neurotransmission. The unique mechanism offers an alternative therapeutic avenue, particularly in patients who do not tolerate PDE5 inhibitors well.

Pharmacological Actions

Selective alpha-2 adrenergic receptor antagonist activity enhancing sympathetic outflow
Increase of norepinephrine release at synaptic junctions
Vasodilation of peripheral vasculature, especially penile arteries
Enhancement of penile erectile function via increased blood flow
Central nervous system stimulant effects through serotonergic and dopaminergic receptor interaction
Elevation of sympathetic nervous system tone increasing heart rate and blood pressure
Modulation of mood and anxiety through central adrenergic pathways
Induction of mydriasis by dilating the pupil via adrenergic stimulation
Thermogenic effects attributed to increased metabolic rate secondary to adrenergic activation
Potential mild diuretic effect linked to enhanced renal sympathetic activity

Therapeutic Or Clinical Uses

Treatment of erectile dysfunction to improve sexual function
Adjunct therapy to increase peripheral blood flow in circulatory disorders
Use in ocular procedures requiring pupil dilation (mydriasis)
Potential off-label use in sexual dysfunction induced by selective serotonin reuptake inhibitors (SSRIs)
Supportive treatment in certain cases of orthostatic hypotension
Investigational uses for enhancing athletic performance and weight loss due to sympathomimetic effects
Management of decreased libido associated with certain psychiatric disorders
Experimental agent in treatment regimens targeting central nervous system neurotransmitter imbalance
Therapeutic intervention in some cases of chronic fatigue syndrome
Alternative therapy in refractory cases of impotence not responding to PDE5 inhibitors

Side Or Adverse Effects

Tachycardia (fast heartbeat) occurring due to increased sympathetic activity
Hypertension or elevated blood pressure
Dizziness especially upon standing, due to vasodilatory effects
Headache commonly reported during treatment initiation
Irritability and increased nervousness or restlessness
Rare gastrointestinal disturbances including nausea and vomiting
Skin flushing attributed to vasodilation
Sweating episodes linked to sympathetic stimulation
Tremor resulting from central nervous system stimulation
Potential exacerbation of anxiety disorders
Palpitations felt as irregular or forceful heartbeats
Insomnia due to central stimulant properties
Rare reports of allergic reactions or hypersensitivity
Possible elevation of liver enzymes in susceptible individuals
Risk of hypertensive crisis in susceptible patients or overdose scenarios

Precautions

Use cautiously in patients with pre-existing cardiovascular disease such as angina or hypertension
Monitor blood pressure regularly due to risk of elevation
Avoid use in patients with psychiatric illness including depression or anxiety disorders
Adjust dosing or avoid in patients with kidney or liver impairment due to altered drug clearance
Caution in elderly patients due to potential for increased sensitivity to central nervous system effects
Use under medical supervision only with consideration for drug-drug interactions
Avoid concomitant use with serotonergic and adrenergic agents that may enhance adverse effects
Patients should report any palpitations, chest pain, or severe headache immediately
Avoid use during pregnancy or lactation unless clearly needed and prescribed by a physician
Do not exceed prescribed doses to minimize risk of serious adverse cardiovascular events
Discontinue use if severe adverse reactions occur
Inform healthcare providers of all medications and supplements to assess interaction risks
Alcohol and tobacco may exacerbate side effects and should be minimized during treatment
Patients with psychiatric or seizure disorders should be monitored closely
Caution in patients with history of drug sensitivity or allergic response

Warnings

Risk of significant increase in blood pressure and heart rate necessitating close monitoring
Potential for CNS overstimulation leading to anxiety, nervousness, or agitation
Avoid use in patients with uncontrolled hypertension or severe cardiovascular disease
Use caution when combined with other sympathomimetic or serotonergic drugs to prevent hypertensive crises
Risk of seizures in susceptible individuals especially with overdose
Possible exacerbation of psychiatric conditions including depression and psychosis
Not approved for use in children and safety has not been established for pediatric populations
Avoid abrupt discontinuation in patients using high doses to prevent rebound hypertension
Discontinue treatment if signs of allergic reaction or severe side effects appear
Use in pregnancy is not recommended due to insufficient safety data
Patients should avoid operating heavy machinery until drug effects are known
May interact with laboratory tests affecting cardiovascular assessments
Risk of peripheral vasoconstriction adverse effects in certain patients
Cardiac arrhythmias, though rare, have been reported
Careful dose titration recommended to minimize adverse reactions

Contraindication

Known hypersensitivity or allergic reaction to yohimbine or related compounds
Severe cardiovascular disease including recent myocardial infarction or uncontrolled hypertension
Patients with active psychiatric illness such as severe depression or psychosis
Use during pregnancy or breastfeeding due to unknown safety
Concomitant use with monoamine oxidase inhibitors (MAOIs)
History of seizure disorders without appropriate control
Severe renal or hepatic impairment where drug clearance is compromised
Patients currently taking drugs with potential significant interactions leading to hypertensive crisis
Use in pediatric patients under 18 years of age
In combination with other sympathomimetic agents without medical supervision
Patients at risk for hypertensive emergency or unstable angina
Presence of pheochromocytoma or other catecholamine-secreting tumors
Severe anxiety disorders exacerbated by adrenergic stimulation
Known intolerance to alpha-2 adrenergic blockers
Patients with autonomic dysfunction disorders

Drug Interactions

Abiraterone Acetate may have increased risk of adverse cardiovascular effects when combined with yohimbine
Desvenlafaxine interaction can enhance hypertensive responses
Duloxetine combined use may potentiate blood pressure elevation
Escitalopram may increase the risk of serotonergic side effects
Fluoxetine interaction increases potential for nervous system excitation and blood pressure rise
Sertraline co-administration may enhance central adrenergic effects
Tocilizumab may interact altering metabolism of yohimbine and its efficacy
Clomipramine can increase risk of hypertension and tachycardia when taken with yohimbine
Clonidine interaction may reduce the antihypertensive effect of clonidine
Guanabenz, Guanadrel, Guanethidine, and Guanfacine may have diminished efficacy due to opposing mechanisms
Lithium levels and neuropsychiatric side effects may be altered
Morphine and related opioids may have enhanced CNS side effects
Naloxone and Naltrexone interactions may affect analgesic efficacy
Reserpine combined use may result in unpredictable blood pressure changes
Ethanol consumption can enhance yohimbine side effects such as dizziness and tachycardia

Preparations Of The Drug

Yohimbine phosphate oral tablets formulated for prescription use
Standard strength oral tablets containing approximately 5.4 mg yohimbine per dose
Compounded formulations may be available for tailored dosing
Veterinary preparations exist but differ from human formulations
Available as single-agent pharmacological preparations
Herbal supplements labeled as Yohimbe contain variable amounts of yohimbine and lack standardization
No widely available injectable or topical formulations for human use
Commercial tablets typically manufactured under Good Manufacturing Practices (GMP)
Prescribed products identified by dosage strength and labeling indicating alpha-2 adrenergic antagonist use
Supplier-provided drug information includes instructions for storage at room temperature away from moisture and light
Packaging designed to maintain stability and prevent degradation
No known extended-release or combination products marketed currently
Product labeling highlights potential side effects and contraindications clearly
Supply chain monitored for quality assurance due to concerns over herbal product adulteration
Patient information leaflets accompany preparations outlining proper usage and warnings